Studies of hepatitis C virus in chimpanzees and their importance for vaccine development.
Persistent infection with hepatitis C virus (HCV) is an important cause of chronic liver disease worldwide. Therefore, the development of vaccines to prevent HCV infection, or at least to prevent progression to chronicity, is a major goal. Potential HCV vaccine candidates include recombinant proteins, recombinant viruses, DNA constructs, synthetic peptides and virus-like particles. Various vaccine candidates have been shown to generate humoral and cellular immune responses in animals, primarily in mice. However, the efficacy of most vaccine candidates in protecting against HCV has not been tested because the chimpanzee, the only animal other than humans that is susceptible to HCV, is not readily available, requires special facilities, and is very expensive. The course of infection in chimpanzees is similar in its diversity to that in humans and detailed studies in this model are beginning to define the immune responses that can terminate HCV infection. Of relevance for vaccine evaluation was the titration in chimpanzees of different HCV variants to provide well-characterized challenge pools. In addition, monoclonal virus pools generated from chimpanzees infected with cloned viruses make it possible now to examine immunity to HCV without the confounding factor of antigenic diversity of the challenge virus (quasispecies). The vaccine trials performed in chimpanzees to date all have tested the efficacy of immunizations with various forms of the envelope proteins of HCV.
Bukh
J
J
Hepatitis Viruses and Molecular Hepatitis Sections, Laboratory of Infectious Diseases, NIAID, National Institutes of Health, Bethesda, Md 20892-0740, USA. jbukh@niaid.nih.gov
Forns
X
X
Emerson
S U
SU
Purcell
R H
RH
D000818:Animals; D002986:Clinical Trials as Topic / Q000662:veterinary; D004195:Disease Models, Animal; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology* / Q000502:physiology; D006526:Hepatitis C / Q000097:blood / Q000276:immunology*; D018937:Hepatitis C Antibodies / Q000096:biosynthesis / Q000276:immunology; D006801:Humans; D009500:Neutralization Tests; D002679:Pan troglodytes / Q000276:immunology* / Q000821:virology*; D014611:Vaccination; D014761:Viral Hepatitis Vaccines / Q000276:immunology* / Q000627:therapeutic use*
D018937:Hepatitis C Antibodies; D014761:Viral Hepatitis Vaccines